Detail akcie Biofrontera Rg online

Business Summary: Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Biofrontera AG revenues increased 15% to EUR12.3M. Net loss decreased 35% to EUR4.1M. Revenues reflect Germany segment increase of 22% to EUR6.7M, USA segment increase of 52% to EUR3.1M. Lower net loss reflects General administrative costs decrease of 65% to EUR1.2M (expense), Research and development costs decrease of 36% to EUR2.9M (expense).